MA35507B1 - Protéines à double fonction pour le traitement de troubles du métabolisme - Google Patents
Protéines à double fonction pour le traitement de troubles du métabolismeInfo
- Publication number
- MA35507B1 MA35507B1 MA36823A MA36823A MA35507B1 MA 35507 B1 MA35507 B1 MA 35507B1 MA 36823 A MA36823 A MA 36823A MA 36823 A MA36823 A MA 36823A MA 35507 B1 MA35507 B1 MA 35507B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- metabolic disorders
- dual function
- metabolic
- related disorders
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000009977 dual effect Effects 0.000 title 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 abstract 3
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000002503 metabolic effect Effects 0.000 abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 abstract 1
- 108010011459 Exenatide Proteins 0.000 abstract 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
- 229960001519 exenatide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne l'identification de protéines de nouvelles protéines comprenant le facteur de croissance des fibroblastes 21 (fgf21) et d'autres régulateurs du métabolisme, y compris des variants de ceux-ci, connus pour améliorer les profils métaboliques chez des sujets auxquels ils sont administrés. L'invention concerne également des procédés de traitement de troubles associés au fgf21, de troubles associés au glp-1 et de troubles associés à l'exendine-4, y compris des troubles du métabolisme.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161539290P | 2011-09-26 | 2011-09-26 | |
| PCT/US2012/057371 WO2013049234A2 (fr) | 2011-09-26 | 2012-09-26 | Protéines à double fonction pour le traitement de troubles du métabolisme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35507B1 true MA35507B1 (fr) | 2014-10-02 |
Family
ID=47023090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36823A MA35507B1 (fr) | 2011-09-26 | 2014-03-13 | Protéines à double fonction pour le traitement de troubles du métabolisme |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9458214B2 (fr) |
| EP (1) | EP2764019B1 (fr) |
| JP (1) | JP6152380B2 (fr) |
| KR (1) | KR102217254B1 (fr) |
| CN (2) | CN104024273B (fr) |
| AP (1) | AP2014007544A0 (fr) |
| AR (1) | AR088165A1 (fr) |
| AU (1) | AU2012316132A1 (fr) |
| BR (1) | BR112014007086A2 (fr) |
| CA (1) | CA2849760A1 (fr) |
| CL (1) | CL2014000737A1 (fr) |
| CO (1) | CO6920258A2 (fr) |
| CR (1) | CR20140141A (fr) |
| CU (1) | CU20140035A7 (fr) |
| EA (1) | EA201490697A1 (fr) |
| GT (1) | GT201400056A (fr) |
| IL (1) | IL231647A0 (fr) |
| MA (1) | MA35507B1 (fr) |
| MX (1) | MX350840B (fr) |
| PE (1) | PE20141542A1 (fr) |
| PH (1) | PH12014500659A1 (fr) |
| SG (1) | SG11201400596QA (fr) |
| TN (1) | TN2014000110A1 (fr) |
| TW (1) | TW201315742A (fr) |
| UY (1) | UY34347A (fr) |
| WO (1) | WO2013049234A2 (fr) |
| ZA (1) | ZA201401699B (fr) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019168A2 (fr) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Acides nucléiques modifiés et leurs procédés d'utilisation |
| EP2625189B1 (fr) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Synthèse d'acides nucléiques et méthodes d'utilisation associées |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| CN105601748B (zh) | 2011-07-01 | 2021-08-27 | 恩格姆生物制药公司 | 用于代谢病症和疾病治疗的组合物、应用和方法 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| UY34347A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| TWI593708B (zh) | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (fr) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Nucleoside, nucleotide, et compositions d'acide nucleique modifies |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2013151665A2 (fr) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Polynucléotides modifiés destinés à la production de protéines associées à une maladie humaine |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013263349B2 (en) | 2012-05-17 | 2016-09-08 | Extend Biosciences, Inc | Carriers for improved drug delivery |
| TW201420606A (zh) * | 2012-08-22 | 2014-06-01 | Lilly Co Eli | 同源二聚體蛋白 |
| JP2015533483A (ja) * | 2012-09-07 | 2015-11-26 | サノフイ | メタボリックシンドロームを治療するための融合タンパク質 |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| HK1214832A1 (zh) | 2012-11-28 | 2016-08-05 | 恩格姆生物制药公司 | 用於代謝病症和疾病治療的組合物和方法 |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| ES2915851T3 (es) | 2012-12-27 | 2022-06-27 | Ngm Biopharmaceuticals Inc | Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2014106846A2 (fr) * | 2013-01-03 | 2014-07-10 | Oramed Ltd. | Procédés et compositions de traitement de la stéatopathie hépatique non alcoolique, de la stéatohépatite et de leurs séquelles |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (fr) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
| EP3052521A1 (fr) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucléotides codant pour un récepteur de lipoprotéines de faible densité |
| CA2927592C (fr) | 2013-10-28 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Variants de fgf-19 pour le traitement d'un cancer ou d'une tumeur fgf-19-dependant |
| PE20170256A1 (es) | 2014-01-24 | 2017-04-22 | Ngm Biopharmaceuticals Inc | Proteinas de union y sus metodos de uso |
| US20170065678A1 (en) | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| PL3129467T3 (pl) * | 2014-04-11 | 2020-05-18 | Université Catholique de Louvain | Wysepki od świni transgenicznej i ich zastosowania w leczeniu cukrzycy |
| WO2015183890A2 (fr) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Méthodes et compositions pour le traitement de maladies et de troubles métaboliques |
| AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| WO2016065042A1 (fr) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Conjugués de vitamine d thérapeutiques |
| RU2729161C2 (ru) | 2014-10-23 | 2020-08-04 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| EA037478B1 (ru) | 2015-08-04 | 2021-04-01 | Дьюк Юниверсити | Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения |
| TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| KR102670157B1 (ko) * | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| SI3402811T1 (sl) | 2016-01-13 | 2022-06-30 | Novo Nordisk A/S | Analogi EGF(A) z maščobnokislinskimi substituenti |
| MX2018014475A (es) * | 2016-05-25 | 2019-05-23 | Univ Texas | Métodos y composiciones para el tratamiento de trastornos secretorios. |
| WO2017210476A1 (fr) | 2016-06-01 | 2017-12-07 | Duke University | Biocapteurs ne s'encrassant pas |
| CN106317226B (zh) | 2016-08-19 | 2017-09-05 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
| CA3034399A1 (fr) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methodes de traitement de cancers et de tumeurs a mediation assuree par le facteur de croissance des fibroblastes 19 |
| WO2018053201A1 (fr) | 2016-09-14 | 2018-03-22 | Duke University | Nanoparticules à base de polypeptide tribloc pour l'administration de médicaments hydrophiles |
| JP2020500150A (ja) | 2016-09-23 | 2020-01-09 | デューク ユニバーシティ | 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド |
| MX2019005380A (es) * | 2016-11-10 | 2019-08-12 | Yuhan Corp | Composicion farmaceutica que comprende proteinas de fusion para prevenir o tratar la hepatitis, la fibrosis hepatica y la cirrosis hepatica. |
| AU2017363321B2 (en) | 2016-11-22 | 2023-09-28 | Klotho Therapeutics, Inc. | Novel recombinant Klotho proteins and compositions and methods involving the same |
| BR112019012693A2 (pt) * | 2016-12-22 | 2019-11-19 | Sanofi | combinações de composto de fgf21/agonista do glp-1r com razão de atividade otimizada |
| WO2018132732A1 (fr) | 2017-01-12 | 2018-07-19 | Duke University | Biomatériaux hybrides lipide-polypeptide génétiquement codés qui offrent un auto-assemblage hiérarchique déclenché par la température |
| CN108440668A (zh) * | 2017-02-16 | 2018-08-24 | 瑞阳(苏州)生物科技有限公司 | Fgf21与igf-1的融合蛋白及其应用 |
| WO2018166461A1 (fr) * | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Protéines de fusion à double cible comprenant la partie fc d'une immunoglobuline |
| US11560416B2 (en) * | 2017-04-21 | 2023-01-24 | Yuhan Corporation | Method for producing dual function proteins and its derivatives |
| WO2018213320A1 (fr) | 2017-05-15 | 2018-11-22 | Duke University | Production recombinante de matériaux hybrides lipidiques-biopolymères qui s'auto-assemblent et encapsulent des agents |
| WO2019006374A1 (fr) | 2017-06-30 | 2019-01-03 | Duke University | Ordre et désordre en tant que principe de conception pour des réseaux de biopolymère sensibles à des stimuli |
| CA3068956A1 (fr) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | Composes bifonctionnels |
| WO2019090209A1 (fr) * | 2017-11-06 | 2019-05-09 | Shire-Nps Pharmaceuticals, Inc. | Analogues de glp-2 et peptibodies destinés à être administrés avant, pendant ou après une intervention chirurgicale |
| CN109836504B (zh) * | 2017-11-24 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多结构域活性蛋白 |
| WO2019119673A1 (fr) * | 2017-12-19 | 2019-06-27 | 北京吉源生物科技有限公司 | Cellule souche modifiée par deux gènes et utilisation de cette dernière |
| WO2019123427A1 (fr) * | 2017-12-22 | 2019-06-27 | Novartis Ag | Procédés de traitement de troubles métaboliques avec des variants de fgf21 |
| CN110028587B (zh) * | 2018-01-11 | 2021-10-08 | 安源医药科技（上海）有限公司 | 用于调节血糖和脂质的增效型双功能蛋白 |
| WO2019147954A1 (fr) | 2018-01-26 | 2019-08-01 | Duke University | Conjugués de médicament-peptidede liaison à l'albumine et méthodes de préparation et d'utilisation de ces derniers |
| AU2019218147B2 (en) | 2018-02-08 | 2023-06-08 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
| EP3788343B1 (fr) | 2018-04-30 | 2024-03-27 | Duke University | Plateforme d'administration de médicament à base de polymère de type peg sensible aux stimuli |
| CU24554B1 (es) * | 2018-05-07 | 2021-11-04 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
| WO2019243557A1 (fr) * | 2018-06-21 | 2019-12-26 | Sanofi | Combinaisons associant le composé fgf21 et un agoniste du glp-1r selon un rapport optimisant leur activité |
| KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
| US12594347B2 (en) | 2018-09-07 | 2026-04-07 | Duke University | Nanoparticulate drug delivery systems |
| JP2022512688A (ja) * | 2018-10-24 | 2022-02-07 | シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド | Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用 |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| JP7495420B2 (ja) * | 2019-02-20 | 2024-06-04 | ノヴォ ノルディスク アー／エス | アミノアシル－ｔＲＮＡ合成酵素およびこの使用 |
| EP3935075A4 (fr) | 2019-03-05 | 2023-01-18 | Sunshine Lake Pharma Co., Ltd. | Molécule polypeptidique et son application |
| CN111944055B (zh) * | 2019-05-16 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| WO2021050789A1 (fr) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Protéines de fusion de ca2-il15 pour une régulation accordable |
| EP4085077A4 (fr) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | Protéines de fusion de glp-1 et de gdf15 et leurs conjugués |
| CN113728013B (zh) * | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| US11981718B2 (en) * | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| AU2021285138A1 (en) * | 2020-06-03 | 2023-02-02 | Københavns Universitet | GLP1R agonist NMDAR antagonist conjugates |
| US20230265152A1 (en) * | 2020-07-02 | 2023-08-24 | Sanofi | Glp-1r agonist / fgf21 fusion proteins |
| CN113105561B (zh) * | 2021-04-30 | 2021-12-03 | 江南大学 | 一种双靶点融合蛋白的制备方法和应用 |
| KR102631925B1 (ko) * | 2021-06-10 | 2024-02-01 | 토드제약 주식회사 | 신규 fgf21 변이체 개발 및 이의 생산기법과 용도 |
| KR20240123816A (ko) * | 2021-12-02 | 2024-08-14 | 쾨벤하운스 유니버시테트 | 퇴행성 신경 질환의 치료를 위한 펩티드-약물 접합체 |
| KR20250075704A (ko) | 2022-09-30 | 2025-05-28 | 익스텐드 바이오사이언시즈, 인크. | 장기-지속형 부갑상선 호르몬 |
| CN120359237A (zh) * | 2022-11-07 | 2025-07-22 | Bp资产Ix股份有限公司 | 用于治疗nash的fgf21蛋白变体 |
| WO2024123812A1 (fr) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Protéines de fusion pour le traitement de maladies cardiométaboliques |
| CN115991793A (zh) * | 2023-01-16 | 2023-04-21 | 上海民为生物技术有限公司 | 具有多重活性的融合蛋白及其应用 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
| JP2583257B2 (ja) | 1986-05-05 | 1997-02-19 | ザ・ジェネラル・ホスピタル・コーポレーション | インシュリン向性ホルモン |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| ATE106249T1 (de) | 1987-11-05 | 1994-06-15 | Hybritech Inc | Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik. |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| EP2163626A1 (fr) | 1999-11-18 | 2010-03-17 | Novartis Vaccines and Diagnostics, Inc. | Gène humain fgf-21 et produits d'expression génique |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| EP1244708B8 (fr) | 1999-12-23 | 2007-03-07 | ZymoGenetics, Inc. | Methode destinee a traiter l'inflammation |
| WO2002085923A2 (fr) | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | Incorporation in vivo d'acides amines non naturels |
| ES2383300T3 (es) | 2003-11-13 | 2012-06-20 | Hanmi Holdings Co., Ltd | Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación |
| EP2270163A1 (fr) | 2003-12-10 | 2011-01-05 | Eli Lilly and Company | Mutéines du facteur de croissance des fibroblastes |
| WO2006036834A2 (fr) * | 2004-09-24 | 2006-04-06 | Amgen Inc. | Molecules fc modifiees |
| EP1846019A2 (fr) * | 2005-01-21 | 2007-10-24 | Eli Lilly And Company | Methode de traitement de maladie cardio-vasculaire |
| CN107501407B (zh) | 2007-03-30 | 2022-03-18 | Ambrx公司 | 经修饰fgf-21多肽和其用途 |
| US20110034373A1 (en) | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| CA2739615C (fr) | 2008-10-10 | 2017-12-05 | Amgen Inc. | Mutants fgf21 et leurs utilisations |
| WO2010048582A1 (fr) | 2008-10-24 | 2010-04-29 | Irm Llc | Pyrroline-carboxy-lysine produite par biosynthèse et modifications de protéines spécifiques de site obtenues par une dérivatisation chimique de pyrroline-carboxy-lysine et de résidus de pyrrolysine |
| WO2010065439A1 (fr) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants de facteurde croissance 21 du fibroblaste |
| PT2373681T (pt) | 2008-12-10 | 2017-04-11 | Glaxosmithkline Llc | Composições farmacêuticas de albiglutida |
| CN102361647B (zh) | 2009-01-23 | 2018-02-16 | 诺沃-诺迪斯克有限公司 | 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用 |
| CN101812474A (zh) * | 2009-02-25 | 2010-08-25 | 李慎涛 | 骨保护素-热休克蛋白65融合蛋白的制备及其应用 |
| WO2010129600A2 (fr) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Mutants de fgf21 et leurs utilisations |
| WO2010129503A1 (fr) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Mutants de fgf21 et leurs utilisations |
| JP2012529463A (ja) | 2009-06-11 | 2012-11-22 | ノヴォ ノルディスク アー／エス | ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ |
| CN101993485B (zh) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| CN101993496B (zh) | 2009-08-20 | 2013-06-05 | 重庆富进生物医药有限公司 | 双重调节血糖血脂融合蛋白及其制法和用途 |
| BR112012017164A2 (pt) | 2009-12-22 | 2019-09-24 | Novartis Ag | proteína de fusão de região constante de anticorpo-cd47 tetravalente |
| EP2460527A1 (fr) | 2010-01-21 | 2012-06-06 | Sanofi | Composition pharmaceutique pour le traitement d'un syndrome métabolique |
| US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| TWI593708B (zh) | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
| UY34347A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| US20170065678A1 (en) | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
-
2012
- 2012-09-25 UY UY0001034347A patent/UY34347A/es not_active Application Discontinuation
- 2012-09-25 TW TW101135181A patent/TW201315742A/zh unknown
- 2012-09-25 US US13/626,207 patent/US9458214B2/en not_active Expired - Fee Related
- 2012-09-26 EP EP12773169.3A patent/EP2764019B1/fr active Active
- 2012-09-26 WO PCT/US2012/057371 patent/WO2013049234A2/fr not_active Ceased
- 2012-09-26 JP JP2014532112A patent/JP6152380B2/ja not_active Expired - Fee Related
- 2012-09-26 KR KR1020147010943A patent/KR102217254B1/ko not_active Expired - Fee Related
- 2012-09-26 BR BR112014007086A patent/BR112014007086A2/pt not_active Application Discontinuation
- 2012-09-26 AP AP2014007544A patent/AP2014007544A0/xx unknown
- 2012-09-26 EA EA201490697A patent/EA201490697A1/ru unknown
- 2012-09-26 PE PE2014000419A patent/PE20141542A1/es not_active Application Discontinuation
- 2012-09-26 MX MX2014003676A patent/MX350840B/es active IP Right Grant
- 2012-09-26 AU AU2012316132A patent/AU2012316132A1/en not_active Abandoned
- 2012-09-26 CN CN201280057819.0A patent/CN104024273B/zh not_active Expired - Fee Related
- 2012-09-26 SG SG11201400596QA patent/SG11201400596QA/en unknown
- 2012-09-26 PH PH1/2014/500659A patent/PH12014500659A1/en unknown
- 2012-09-26 AR ARP120103552A patent/AR088165A1/es unknown
- 2012-09-26 CN CN201610821947.8A patent/CN106432510A/zh active Pending
- 2012-09-26 CA CA2849760A patent/CA2849760A1/fr not_active Abandoned
-
2014
- 2014-03-07 ZA ZA2014/01699A patent/ZA201401699B/en unknown
- 2014-03-12 TN TNP2014000110A patent/TN2014000110A1/en unknown
- 2014-03-13 MA MA36823A patent/MA35507B1/fr unknown
- 2014-03-20 IL IL231647A patent/IL231647A0/en unknown
- 2014-03-25 CL CL2014000737A patent/CL2014000737A1/es unknown
- 2014-03-26 CO CO14064524A patent/CO6920258A2/es unknown
- 2014-03-26 CR CR20140141A patent/CR20140141A/es unknown
- 2014-03-26 CU CU2014000035A patent/CU20140035A7/es unknown
- 2014-03-26 GT GT201400056A patent/GT201400056A/es unknown
-
2016
- 2016-08-26 US US15/248,712 patent/US10669323B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35507B1 (fr) | Protéines à double fonction pour le traitement de troubles du métabolisme | |
| MA35437B1 (fr) | Proteines de fusion pour le traitement de troubles du metabolisme | |
| MA34710B1 (fr) | Procede de traitement des troubles associes au fgf21 | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| EP4603144A3 (fr) | Administration peripherique de genes du cns utilisant des vecteurs aav | |
| PH12018502451A1 (en) | Brain delivery protein | |
| MY171300A (en) | Pharmaceutical composition | |
| EA033387B1 (ru) | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 | |
| MY171135A (en) | Antibodies specific for tgf-beta | |
| EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| MA38478A1 (fr) | Anticorps anti-pac1 humains | |
| MY153062A (en) | Methods of treating gastrointestinal disorders independent of the intake of food | |
| EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
| MA45172B1 (fr) | Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées | |
| WO2023178280A3 (fr) | Compositions et méthodes de modulation de l'expression de l'alpha-synucléine | |
| EA202190334A1 (ru) | Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением | |
| JOP20200046A1 (ar) | طرق لعلاج أمراض مرتبطة بـtnf? | |
| WO2012173781A3 (fr) | Méthodes de traitement des troubles du métabolisme du glucose | |
| MA37640B1 (fr) | Protéines du facteur de croissance des fibroblastes 21 | |
| TN2013000211A1 (en) | Methods of treating fgf 21- associated disorders | |
| ATE535246T1 (de) | Zusammensetzung zur behandlung von erkrankungen des zentralen nervensystems | |
| TH1401006878A (th) | รีคอมบิแนนท์ อะดีโน-แอสโซซิเอเทดไวรัส (rAAV) เว็คเตอร์สำหรับใช้ในการบำบัดรักษาโรคการสร้างหลอดเลือดใหม่ของตาในผู้ป่วย ที่เคยได้รับสารยับยั้ง VEGF | |
| UA92465C2 (ru) | Терапевтические применения ингибиторов rtp801 |